Enliven Therapeutics, Inc.
ELVN
$20.32
$0.3751.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.87M | 24.56M | 23.78M | 21.13M | 18.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.24M | 110.26M | 104.55M | 99.09M | 94.97M |
| Operating Income | -114.24M | -110.26M | -104.55M | -99.09M | -94.97M |
| Income Before Tax | -100.22M | -94.60M | -88.79M | -84.98M | -82.60M |
| Income Tax Expenses | 0.00 | 232.00K | 232.00K | 232.00K | 232.00K |
| Earnings from Continuing Operations | -100.22 | -94.83 | -89.02 | -85.21 | -82.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.22M | -94.83M | -89.02M | -85.21M | -82.83M |
| EBIT | -114.24M | -110.26M | -104.55M | -99.09M | -94.97M |
| EBITDA | -113.93M | -109.95M | -104.24M | -98.77M | -94.65M |
| EPS Basic | -2.00 | -1.93 | -1.90 | -1.91 | -1.93 |
| Normalized Basic EPS | -1.26 | -1.22 | -1.21 | -1.18 | -1.18 |
| EPS Diluted | -2.00 | -1.93 | -1.90 | -1.91 | -1.93 |
| Normalized Diluted EPS | -1.26 | -1.22 | -1.21 | -1.18 | -1.18 |
| Average Basic Shares Outstanding | 200.28M | 196.25M | 188.25M | 179.52M | 172.28M |
| Average Diluted Shares Outstanding | 200.28M | 196.25M | 188.25M | 179.52M | 172.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |